Utilizing Software Modules as an Enhancement to Pharmaceuticals for Chronic Conditions Is Poised to Be Critical Component of Digital Healthcare

NEW YORK, NY–(Marketwired – Oct 6, 2016) – Psilos Group, in its seventh annual Outlook outlining major emerging healthcare trends, says digital therapeutics is a $6 billion market opportunity by 2021. Digital therapeutics — “software as a drug” — deploys software modules as an enhancement, or even a substitute, to a drug. It is poised to become a critical component of digital health and to substantially improve the efficiency of American healthcare. Continue

Pear Therapeutics CEO, Corey McCann MD PhD, to speak at the 13th Annual Connected Health Symposium

Health, technology, research, human behavior and public policy intersect at Connected Health Symposium 2016.  Over 1,000 visionaries, leaders, practitioners and thinkers will gather for the 13th year at this premier destination event hosted by Partners HealthCare Connected Health. The 13th Annual Connected Health Symposium: Digital Technology that Cares: Bringing the Human Element to Life October 20-21, 2016, at Boston’s Seaport Hotel and World Trade Center Continue    

The Largest and Longest Study of Patients with Schizophrenia Interacting with Digital Therapeutics Results Released

Pear Therapeutics to Bring to Market Digital Therapeutics Based on Clinical Research from Dr. Dror Ben-Zeev et al for Patients with Severe Mental Illness BOSTON, MA and SAN FRANCISCO, CA – Pear Therapeutics (PEAR), the creator of prescription digital therapies called eFormulationsTM, announced today results from a real-world implementation study examining a research version of THRIVETM, PEAR’s digital therapy for treating patients with Serious Mental Illness including schizophrenia, schizoaffective disorder, and bipolar disorder. Continue

PEAR’s Substance Use Disorder therapy, reSETTM, featured in Neurotech Insights

Pear Therapeutics Advances the First Regulated Digital Therapies for Addiction Pear Therapeutics has grown significantly over the past year and now boasts forty employees split between the Boston, MA office and the San Francisco, CA location. NeuroInsights caught up with Dr. Corey McCann, founder and CEO, to learn about Pear’s progress developing digital therapeutics. Continue

To FDA or Not to FDA is Hot Topic at Neurogaming Conference

By Lesley McClurg Wandering through booths at a neurogaming conference in downtown San Francisco this week was a little like finding myself in a science fiction infomercial. This was the  the fourth annual Experiential Technology & NeuroGaming Conference and Expo, where I mingled with neuroscientists and inventors, eager to explain the technology behind their multiwired headsets or sleek brain gadgets. Continue

Pear Therapeutics CEO, Corey McCann, to Speak at Digital Health Summer Summit

The Fifth Annual Digital Health Summer Summit, co-located this year with BIO International Convention at the Moscone Center in San Francisco takes a deep dive into the elements of a successful digital health venture and showcases the latest digital health innovations from the industry’s most brilliant leaders and organizations who will explore the issues and opportunities facing the industry. Continue

Pear Therapeutics Closes $20 Million Financing

BOSTON, MA and SAN FRANCISCO, CA – Pear Therapeutics (PEAR), the creator of prescription digital therapies called eFormulationsTM, announced today that it has successfully closed on a $20M equity financing. 5AM Ventures, Arboretum Ventures, and JAZZ Venture Partners led the round, with participation from Bridge Builders Collaborative and several additional investors. The investment will allow PEAR to build and launch a portfolio of eFormulations, including reSETTM and reSET-OTM, PEAR’s digital therapies for treating Substance Use Disorder (SUD). “PEAR is at the forefront of a new field in medicine, digital therapeutics, and we are looking forward to working with the PEAR … Continue reading

Video game designers tout games as prescription therapies

Inside the push for prescription video games to treat autism, anxiety, even Alzheimer’s By: Rebecca Robbins Hundreds of patients with mental illness are signing up to test an unusual experimental treatment: video games. It’s part of a bold push by several companies, led by two Boston startups, to secure permission from federal regulators to market their video games as medical therapies, to be prescribed by physicians for conditions ranging from depression to autism to even, perhaps, Alzheimer’s disease…   Continue

Pear Therapeutics Advisor, Patrick J. Kennedy, to speak at Cambridge Public Library on Thursday, October 22, 2015 at 7:00pm

Harvard Book Store will welcome former congressman, Patrick J. Kennedy, for a discussion of his book A Common Struggle: A Personal Journey Through the Past and Future of Mental Illness and Addiction, co-authored with Stephen Fried. Event Details: Cambridge Public Library 449 Broadway Cambridge, MA 02138 7:00 pm Event Flyer

Pear Therapeutics featured in latest issue of Neurotech Insights

Pear Therapeutics CEO, Corey McCann MD, PhD, was interviewed during the 3rd European Neurotech Investing and Partnering Summit held on September 9-10 in Geneva, Switzerland. Read Full Article Here